Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JX-594 plus best supportive care versus best supportive care in sorafenib-failed advanced hepatocellular carcinoma
2011-000051-16Phase 2Terminated
- Sponsor
- Jennerex Therapeutics
- Start
- Nov 2011
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing JX-594 plus best supportive care with Best supportive care (2 arms). Primary endpoint: Overall survival. Started Nov 2011; status: terminated.
02
Drugs
vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2011-000051-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000051-16.